---
document_datetime: 2023-09-21 17:33:46
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tasermity-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: tasermity-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3059297
conversion_datetime: 2025-12-28 20:10:00.876256
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tasermity

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------|
| N/0006               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 15/12/2017                          |                                                | Labelling and PL                 |                                                                                                                        |
| PSUSA/2697/ 201610   | Periodic Safety Update EU Single assessment - sevelamer                                          | 09/06/2017 product                  | n/a                                            |                                  | PRAC Recommendation - maintenance                                                                                      |
| PSUSA/2697/ 201510   | Periodic Safety Update EU Single assessment - sevelamer                                          | 23/06/2016                          | 25/08/2016                                     | SmPC                             | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |               |                    | PSUSA/2697/201510.                                                                                                                                                                                                                                                                                           |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0867 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.5 of the SmPC regarding drug-drug interaction between sevelamer and proton pump inhibitors. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in section 4.8 of the SmPC of Renvela and Sevelamer carbonate Zentiva in order to harmonize the wording for all Sevelamer compounds. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 11/02/2016 | 25/08/2016 no | SmPC and PL longer | Changes in gastric acidity with acid suppressants may potentially alter the efficacy of sevelamer HCL. During post-marketing experience, very rare cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer hydrochloride. authorised |
| WS/0803 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required Medicinal product                                                                                                                                                                                  | 19/11/2015 | n/a           |                    |                                                                                                                                                                                                                                                                                                              |
| WS/0770 | This was an application for a variation following a worksharing procedure according to Article 20 of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 01/10/2015 | 25/08/2016    | SmPC and PL        |                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

<!-- image -->